
|Videos|February 27, 2017
Medicare Part D and Oncology
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Advertisement
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cyclosporiasis on the Rise in the United States, Exceeding 450 Cases
2
Same-Day COVID-19 and Flu Vaccination Does Not Raise Adverse Event Risk, Large VA Study Finds
3
Study Links Several Progestogen Contraceptives to Rare Meningioma Risk, Reinforcing Individualized Patient Counseling
4
Reducing Recurrence in C Difficile Infection
5











































































































